Checkpoint blockade therapies, such as PD-1/PD-L1 inhibitors (e.g., nivolumab, pembrolizumab, atezolizumab), have revolutionized HCC treatment, yet their effectiveness varies between male and female patients (26, 27). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.